Note: Descriptions are shown in the official language in which they were submitted.
CA 02342305 2001-04-20
PESTIVIRUS MUTANTS AND VACCINES CONTAINING THE SAME
The present invention is directed to attenuated pestivirus mutants, which have
a
reduced ability to replicate, which is exhibited by a small plaque size. Such
viruses are
useful as live vaccines in the control of bovine viral diarrhea, classical
swine fever and
border disease of sheep. The invention is particularly directed to attenuated
bovine viral
diarrhea viruses that have been genetically engineered for reduced replication
in the
host, and which are useful in live vaccines for cattle.
Pestiviruses cause economically important diseases in animals worldwide. The
genus Pestivirus, within the family Flaviviridae, comprises three species:
bovine viral
diarrhea virus (BVDV), classical swine fever virus (CSFV), and border disease
virus
1 r-
(BDV). The presence of a fourth separate group of pestiviruses comprising
isolates
from cattle and sheep has been recently described, and it is now generally
accepted to
refer to this additional species as BVDV-2; consequently, classical BVDV
strains are
named BVDV-1. See Becher et al., Virology 209(1):200-206 (1995).
BVDV-1 and BVDV-2 both cause acute infections in cattle (diarrhea, fever,
hemorrhagic syndrome) as well as (if the infection occurs during pregnancy)
abortion,
malformation of the fetus and persistent infection of the calves. Persistently
infected
animals represent the major reservoir of the virus, and such animals may come
down
with the fatal mucosal disease (MD).
2 5>
Classical swine fever virus (CSFV), formerly called hog cholera virus, is
responsible for classical swine fever (CSF) or hog cholera (HC). Border
disease virus
(BDV) is typically found in sheep and causes border disease (BD). Symptoms
similar to
MD in cattle have also been shown to occur after intrauterine infection of
lambs with
3 0 BDV. For a review of pestiviruses, see Thiel et al., The pestiviruses., In
Fields Virology,
Fields et al. (eds.) (Lippincott-Raven, Philadelphia), pp.1059-1073 (1996).
Vaccines based on live or killed viruses, as well as of recombinant expression
systems expressing viral proteins., have been developed for BVDV and CSFV and
are
3 presently used. The presently used live vaccines contain a more or less
attenuated
strain that replicates in the host. Attenuation may have been achieved by
multiple
passaging in homologous or heterologous cell culture (at suboptimal
temperatures).
1
CA 02342305 2001-04-20
However, these strains may still lead to transplacental infection and thereby
cause fetal
death, growth malformation, and persistant infection in the offspring.
A live vaccine strain with defined mutations resulting in a strong attenuation
would avoid the disadvantages of the present generation of vaccines. Full-
length
infectious DNA copies have recently been constructed for BVDV (Meyers et at.,
J. of
Virology 70:8606-8613 (1996)) and CSFV (Meyers et at., J. of Virology 70:1588-
1595
(1996)). Their availability enables scientists to perform reverse genetic
engineering in
order to develop attenuated strains of BVDV or CSFV. However, it is still not
known
which region(s) of the genome should and can be modified to lead to a safe and
effective vaccine strain.
Because of the importance of a safe and effective prophylaxis and treatment of
pestivirus infections, there is a strong need for live and specifically
attenuated vaccines
1 I5 with a high potential for induction of immunity as well as a defined
basis of attenuation
resulting in a significant reduction in the ability to replicate in the host.
Therefore, the technical problem underlying the present invention is to
provide
safe, specifically attenuated pestiviruses for use as live attenuated vaccines
with an
2 0 ability to induce protective immunity.
The solution to the above technical problem is achieved by the present
invention,
which provides an attenuated pestivirus which contains a mutation in the
5'nontranslated
region (NTR) of the pestivirus genome.
More specifically, the present invention is directed to a pestivirus which
contains
one or more mutations in the region containing stem-loops la and lb of the 5'
nontranslated region (NTR) of the pestivirus genome, which mutation results in
a small
plaque size phenotype, in which the expression of the viral polyprotein is
under the
3 0 control of a homologous internal ribosome entry site (IRES) and the
sequence GUAU is
at the 5' end of the pestivirus genome.
Complementary bases of single-stranded RNA can pair to form stem-loop
structures, also referred to as hairpins. Two such stem-loop structures,
termed la and lb
31-D (or B1' and B1, respectively, by some authors), appear at the 5' non-
translated region of
pestiviruses, and precede the IRES element. See Figure 1 B, which shows the
secondary structure of the 5' NTR of BVDV). For BVDV, the stem-loops la and lb
comprise roughly nucleotides 1 - 73 of the BVDV genome. By the present
invention, it
2
CA 02342305 2001-04-20
has been discovered that the region containing these stem-loop structures is
not
essential for viral replication.
The IRES element is where translation initiation of the pestivirus polyprotein
occurs, and is located within the 5'NTR and the 5' terminal region of the open
reading
frame (ORF). The 5' border of the pestivirus IRES is near nucleotide 75; the
5' terminal
stem-loops la and lb are not required for IRES activity. See Chon et al.,
Virology
251:370-382 (1998). There is a general agreement that the 3' end of the IRES
extends
to the AUG initiation codon of the polyprotein.
Although the examples herein are directed to BVDV, the present invention is
contemplated as applicable to all of the pestiviruses. This is particularly
because BVDV,
CSFV and BDV are structurally and serologically related to one another. The
overall
genetic relatedness among the pestiviruses is well defined by the extent of
sequence
1 homology between the genomes of the viruses of this genus, which is 60-70%.
More
significantly, the primary and secondary structures of the 5'NTR of
pestiviruses are
similar. That is, the stem-loop structures in this region are the same. See
Deng et al.,
Nucleic Acids Res., 21:1949-1957 (1993); Becher et al., J. Virol. 72:5165-5173
(1998);
and Pestova et al., Genes & Development 12:67-83 (1998).
By the term "mutation" is meant that there is a change in the nucleic acid
sequence as compared to the parent, wild-type virus, and may be a
substitution,
insertion and/or deletion of nucleotides. The mutation(s) is such that the
virus exhibits a
small plaque size phenotype in comparison to a typical wild-type strain. The
mutation is
2.5 made in the 5'NTR of the pestivirus genome, in the region containing stem-
loops la and
lb. Thus, the IRES is not affected and the viral polypeptide can still be
translated.
Therefore, the mutated virus may produce the full complement of pestiviruses
proteins,
allowing for maximum immunogenicity of the attenuated virus when used as a
vaccine.
On the other hand, mutations in addition to those in the 5' NTR stem-loop la
and lb
3 3 region occurring in the polyprotein region of the pestivirus genome, which
result in non-
functionality or non-expression of a viral protein, are also contemplated by
the present
invention. Such pestivirus mutants could function as marker vaccines.
By "small plaque size" phenotype is meant that the pestiviruses exhibit
plaques
33 that are on average at least about 50% smaller than the parent, wild-type
virus under
identical conditions. Such a reduced plaque size is indicative of a growth-
restricted
phenotype, and thus a significant decrease in virulence. Plaque size can be
determined
by the following method. A host cell line (in particular, MDBK for BVDV) is
transfected
3
CA 02342305 2001-04-20
with 2 g of RNA which has been synthesized in vitro from full-length cDNA
infectious
clones, and 10-fold serial dilutions of transfected cells together with 2 X
106 untreated
cells are seeded into six-well dishes. After incubation at 37 C for 4 hours,
the attached
cells are overlaid with semisolid medium containing 0.6% low-melting-point
agarose and
5% horse serum. After 6 days of incubation at 37 C, the agarose overlays are
removed,
and the plaques can be visualized by, for instance, an immunostain. Plaque
sizes are
measured and an average plaque size can then be determined.
Typically, the average plaque size of pestiviruses is about 3 - 4 millimeters,
by
the above assay. Thus, for the present invention, in order to be considered as
having a
small plaque size phenotype, the average plaque size for the mutant should be
between
0.2 and 2.0 mm, preferably between 0.5 and 1.5 mm, more preferably between 0.7
and
1.2 mm, and most preferably about 0.8 mm in plaque size based upon the above
described plaque assay.
l5
The mutants of the present invention should have a homologous IRES. This
means that the mutants should have a pestivirus IRES, whether its own or that
of
another pestivirus. Thus, a mutant BVDV could have a BVDV IRES element or a
CSFV
or BDV IRES element. Preferably, however, the pestivirus mutant of the present
invention contains its own IRES element (i.e., BVDV mutants have a BVDV IRES,
CSFV
mutants have a CSFV IRES, etc.)
It is required that the 5' end of the genome of the pestivirus mutant have the
sequence 5'-GUAU. This sequence was found by the present inventors to be
necessary
2 5 for replication; without this sequence replication is severely reduced,
and therefore not
amenable to vaccine production. It was also found by the present inventors,
however,
that if the entire region preceding the IRES (i.e., stem-loops la and lb) was
deleted,
replication was severely reduced even with the presence of the 5'-GUAU
sequence.
(This is in contrast to Frolov et al., RNA, 4:1418-1435 (1998), which showed
that BVDV-
3 0 HCV chimeras that contained the GUAU sequence but did not contain BVDV
stem-loops
la and Ib, were not dramatically altered in replication ability.) Such mutants
are,
therefore, not contemplated in the present invention.
Preferably, the pestivirus of the present invention has one or more mutations
in
3 5 stem-loop la or in stem-loops la and lb of the 5'NTR. These stem-loop
structures are in
the region 5' to the IRES, and are shown in Figure 1 B. It was found by the
present
inventors that if the conserved sequence motif 5'-GUAU was retained at the
5'end of the
genomic RNA, 5'NTR sequences with substitutions or deletions of various parts
of stem-
4
CA 02342305 2001-04-20
loop la or deletion of the entire la with part of Ib supported replication,
but to a lower
degree than the parent virus. On the other hand, if the entire loop region of
lb is
deleted, there is almost a complete loss of replication.
Preferably, more than one mutation is made in the 5'NTR of the pestivirus. It
is
known that viruses with more than one mutation, in the case of a substitution
or insertion.
for instance, are more genetically stable than those with just one mutation.
More preferably, the pestivirus of the present invention has a deletion of one
or
more nucleotides. In particular, one can delete nucleotides 5 - 28 (with the
numbering
used in this specification being based on the genomic sequence of BVDV-1,
strain CP7-
5A, which is the same as the sequence shown in Figure 1A as CP7-9A but with 4
fewer
A residues after nucleotide 44) of stem-loop la and obtain mutants with the
desired
reduction in replication. Even more preferable are mutants with larger
deletions, such
as A 2 - 31 (in other words a deletion of stem-loop Ia, but still having GUAU
at the 5')
and A 5 - 57 (in other words, a deletion of stem-loop la and part of stem-loop
Ib, but
retention of the GUAU found in nucleotides 1 - 4 of stem-loop la). Other
preferred
mutants are those that have nucleotides 5 - 73 deleted (i.e., have stem-loops
la and lb
deleted, leaving only the GUAU sequence 5' to the IRES), but that have either
the
sequence AU or CCU inserted between the GUAU and the 5' end of the IRES. That
is,
the 5' terminal sequence in these mutants is either GUAUAU or GUAUCCU. See
Figure
6D, clones M1 and M2. Most preferred of the deletion mutants is A 2-31.
Preferably, when the loop portion of stem-loop lb (i.e., the region downstream
of
nucleotide 44 for BVDV-1, CP7 strain) is present in the mutant of the present
invention,
there are only five adenosine (A) residues present in it. The inventors
surprisingly found
that five A residues results in a genetically stable BVDV in this loop region.
Of course,
genetic stability is important for live vaccines.
Preferably, the pestivirus of the present invention is BVDV-1 or BVDV-2.
The pestiviruses according to the present invention can be prepared using so-
called "reverse genetic" techniques. Genetically manipulating the RNA of
pestiviruses in
vitro is not currently possible. However, cDNA can be synthesized from the RNA
of the
virus and cloned into a plasmid by techniques known in the art. Such
constructs are
known as infectious clones, because the cDNA clones can transcribe RNA in
vitro which
generates infectious virus in cells. Using infectious clones, one can
manipulate the DNA
to engineer mutant viruses. This technique is called reverse genetics.
5
CA 02342305 2001-04-20
Infectious clones of BVDV' and CSFV are known (see the two Meyers et al.
references, cited supra), and it is expected that BDV infectious clones can be
constructed based on the same techniques. The infectious clones can be
transfected
into a cell culture suitable for growth of the virus. For example, infectious
clones of
BVDV can be transfected into bovine kidney cells (such as MDBK cells);
infectious
clones of CSFV can be transfected into porcine kidney cells (for example, PK-1
5 or SK-
6). BDV clones could be similarly transfected into ovine or bovine cells.
Using the infectious clones, one can substitute, insert or delete nucleotides
in the
5'NTR in accordance with the present invention using standard techniques, such
as
techniques for site-directed mutagenesis. A reduced ability to replicate can
be
ascertained with the mutants by measuring specific infectivity (i.e., the
number of plaque
forming units (PFUs) per p.g RNA) or the TCID50 in an appropriate cell
culture. The small
plaque phenotype can be determined by the plaque assay described above in this
specification.
The present invention also encompasses vaccines comprising the pestivirus
mutants. The term "vaccine" as used herein refers to a pharmaceutical
composition
comprising at least one immunologically active component that induces an
immunological response in an animal and possibly, but not necessarily,
additional
components that enhance the immunological activity of the active component.
The
vaccine also comprises additional components typical to pharmaceutical
compositions.
2 5 The pestivirus mutants of the present invention can be formulated into
vaccines
that comprise an effective dosage of live attenuated pestivirus, i.e. an
amount of
pestivirus that will induce immunity in the vaccinated animals against
challenge by the
virulent pestivirus, and comprises a pharmaceutically acceptable carrier or
diluent, for
example, physiological saline solution. Immunity is defined herein as the
induction to a
significant degree of a higher level of protection in a population of animals
after
vaccination as compared to an unvaccinated group. The precise dosage can be
determined by the practitioner; a typical dose of live virus for a cattle
vaccine, for
instance, is between 5 and 7 log,, TCID50 per dose.
3 5 To produce sufficient quantities of the virus mutants for vaccine
purposes, the
mutants can be grown in suitable cell culture and for example, in roller
bottles or
fermentators, with or without microcarriers.
6
CA 02342305 2001-04-20
Carriers in the vaccine composition may comprise
stabilizers, preservatives and buffers. Suitable stabilizers are, for example,
SPGA,
carbohydrates (such as sorbitol, imannitol, starch, sucrose, dextran,
glutamate or
glucose), proteins (such as dried milk, serum albumin, casein, or proteins
from other
sources such as from plants or microorganisms), or degradation products
thereof.
Suitable buffers are, for example, alkali metal phosphates. Suitable
preservatives are
thimerosal, merthiolate and gentamicin. Diluents include water, aqueous buffer
(such as
buffered saline), alcohols and polyols (such as glycerol).
If desired, the live vaccine! compositions according to the invention may
contain
an adjuvant. Non-limiting examples of suitable compounds and compositions with
adjuvant activity include aluminum hydroxide, -phosphate, or -oxide, oil-in-
water or
water-in-oil emulsions based on, for example, a mineral oil, such as Bayol or
Marcol
or a vegetable oil such as vitamin E acetate, and saponins.
The vaccine according to the present invention may also contain one or more
other immunogens of other microorganisms which are pathogenic to the animal
being
immunized. For instance, for cattle, additional immunogens can be derived from
one or
more of bovine rotavirus, bovine respiratory syncytial virus, bovine
herpesvirus type 1,
bovine coronaviruses, parainfluenza type 3 virus, bovine paramyxovirus, foot
and mouth
disease virus and Pasteurella hernolytica. For swine, such combination
vaccines could
include foot and mouth disease virus, pseudorabies virus, Pasteurella
multocida,
Erysipelas rhusiopathiae, and Actinobacillus pleuropneumoniae. For sheep,
additional
immunogens could be those from Toxoplasma and Chlamydia psittaci.
The vaccine may be in the form of a solution, suspension, or in a lyophilized
or
frozen form, and prepared using standard techniques. Both the preparation of
the live
pestivirus and the formulation of this with other immunogens, with or without
adjuvant,
are conventional, and include the mixing of the live attenuated pestivirus
with a
pharmaceutically acceptable carrier or diluent, optionally with other
immunogens and
optionally with an adjuvant. The preparation of vaccine compositions is inter
alia
described in "Handbuch der Schutzimpfungen in der Tiermedizin" (eds: Mayr, A.
et al.,
Verlag Paul Parey, Berlin and Hamburg, Germany, 1984) and "Vaccines for
Veterinary
Applications" (eds: Peters, A.R. et al., Butterworth-Heinemann Ltd., 1993).
For
3 s instance, as a non-limiting example, the vaccine could be prepared as
follows: Cell
culture supernatant containing the mutant pestivirus according to the
invention is mixed
with a stabilizer, and the mixture is subsequently lyophilized or dehydrated
by other
7
CA 02342305 2001-04-20
methods. Prior to vaccination, said mixture is then rehydrated in aqueous or
non-
aqueous solutions.
The present invention provides vaccines, or pharmaceutical compositions, which
are particularly useful for the prophylaxis and treatment of pestivirus
infections in
animals. Therefore, a further aspect of the present invention relates to
methods for the
prophylaxis and treatment of pestivirus infections in animals characterized in
that a
vaccine according to the present invention is administered to an animal in
need of such
prophylaxis or treatment. The vaccines of the present invention can be
administered by
intramuscular or subcutaneous injection or via intranasal, intratracheal,
oral, cutane,
percutane or intracutane administration. Preferably, for BVDV vaccines,
vaccination is
intranasal or intramuscular, intramuscular being most preferred. Live vaccines
for BVDV
are preferably administered between about six months of age and the first
insemination
in dairy cattle.
The present invention is further characterized by reference to the following
examples, it being understood that the invention is not limited thereto.
EXAMPLE 1: Generation of infectious cDNA clones of BVDV and resulting CP7-5A
virus
(A) Generation of infectious cDNA clone of BVDV
After cDNA cloning of the genome of bovine viral diarrhea virus strain CP7,
the
2 5 full-length cDNA clone pA/BVDV was constructed (described in detail by
Meyers et al.,
J. Virol. 70: 8606-8613). The 5' terminal sequence of the CP7 genomic RNA
comprising
the 5' proximal 21-23 nucleotides (nt) and the 3' terminal 33 nt (when
compared to
published sequences of other BVDV strains) were not determined; instead the
respective terminal sequences of the heterologous BVDV-1 strain NADL were
introduced into pA/BVDV.
(B) Generation of the infectious cDNA clone pCP7-5A
In order to establish an authentic infectious cDNA clone of BVDV CP7, the 5'
3 5 and 3' terminal sequence of this virus were determined. After ligation of
the viral
genomic RNA, a nested RT-PCR assay (using sense primers located at the 3' end
of
the genome and antisense primers located in the 5' NTR of the genome) resulted
in
specific amplification of a cDNA fragment of the expected size which was
subsequently
8
CA 02342305 2001-04-20
cloned in a bacterial vector. Sequence analysis revealed that the unknown 5'
terminal
21 nt differed at 9 positions from the sequences of BVDV-1 strains NADL and
Osloss
(Fig. 1 A). Surprisingly, the ten clones analyzed for determination of the 5'
and 3'
terminal sequences of BVDV CP7 exhibited a marked variation with respect to
the
number of A residues following nucleotide position 44. While the previously
reported
CP7 full-length cDNA clone pA/BVDV comprised 8 A residues at this position, 9
to 26 A
residues were present in the cDNA clones obtained in this study. With respect
to the 3'
terminal 33 nt of the CP7 genome, six nucleotide differences were found when
compared to the 3' terminus of BVDV NADL, while only two nucleotides differed
from
the sequence of BVDV strain Osloss.
The BVDV CP7 full-length cDNA clones described here were constructed on the
basis of pA/BVDV (see reference above) and the subgenomic cDNA clone HHDI9
(described in detail by Tautz et al., J. Virol. 73, 9422-9432) which contains
a Nhel-site
and an SP6 RNA polymerase promoter immediately upstream of the viral cDNA.
HHDI9
lacks the genomic region encoding the structural proteins as well as p7 and
NS2; the 5'
terminal 21 bases and the 3' terminal 33 bases of HHDI9 were derived from the
BVDV
Osloss sequence. An Xhol (nt 222-227 of the CP7-5A sequence)/ Clal (nt 11075-
11080
of the CP7-5A sequence) fragment from pA/BVDV was inserted in plasmid HHDI9
2 C predigested with Xhol and Clal, resulting in the plasmid pCP7-Os. For
construction of
CP7 full-length cDNA clones carrying the authentic 5' terminus and 9, 20, and
26 A
residues downstream of position 44, the respective cDNA clones obtained after
RNA
ligation/RT-PCR were used as templates for PCR with 01 200R (corresponding to
nt
235-252 of the CP7-5A sequence) and 01 CP7-SP6 (5'-
TACGCTAGCATTTAGGTGACAC:TATA GTATACGAGGTTAGGCAAGTTC-3"; the
underlined region corresponds to nt 1-22 of the CP7-5A sequence; an SP6 RNA
polymerase promoter preceded by a Nhel-site is located directly upstream of
the CP7-
specific sequence). Finally, the Nhel/Xhol fragment of pCP7-Os was replaced by
the
CP7-specific Nhel/Xhol fragments carrying 9, 20, and 26 A residues following
position
44, resulting in the full-length cDNA clones pCP7-9A, pCP7-20A, and pCP7-26A.
Infectious BVDV was recovered after transfection of full-length RNA
transcribed
in vitro from the cDNA constructs pCP7-9A, pCP7-20A, and pCP7-26A. For
transcription
of RNA, the full-length cDNA clones were digested to completion with Smal,
extracted
with phenol-chloroform and precipitated with ethanol. One microgram of
linearized
plasmid DNA was transcribed with SP6 RNA Polymerase in 20 pl using standard
conditions. For degradation of the template DNA, the reaction mixture was
digested with
5 U of DNase I for 1 h at 37 C, followed by extraction with phenol-chloroform
and
9
CA 02342305 2001-04-20
precipitation with ethanol. Photometric quantification of the transcribed RNAs
was
carried out in a photometer. The quality and the calculated amount of each RNA
were
controlled by ethidium bromide staining of samples after agarose gel
electrophoresis.
RNA transcripts used for transfection contained > 60% of full-length RNA. MDBK
cells
(obtained from the American Type Culture Collection, Rockville, Md., USA) were
transfected by electroporation. For transfection, the confluent cells from a
10-cm-
diameter dish were resuspended in 0.4 ml of PBS without Ca2+ and Mgt+, and
mixed with
2 pg of in vitro transcribed RNA immediately before the pulse (950 F and 180
V). The
transfected cells were seeded on 2 six-well dishes and adjusted to 2 ml with
medium
lo containing 10 % horse serum. After transfection of cells, the production of
progeny virus
was indicated by development of cytopathology. Infection of the transfected
cells was
confirmed by immunfluorescence analysis (IFA) using monoclonal antibodies
against
Erns, E2, and NS3/NS2-3 and by passaging of the recovered infectious virus.
1E-
To investigate the genetic stability of the 5' NTR mutants, the obtained
viruses
CP7-9A, CP7-20A, and CP7-26A were repeatedly passaged in MDBK cells and the
lengths of 5' NTR fragments were determined after 10 passages by RT-PCR
analysis
using primers 01 200R and 01 CP'7-SP6 and subsequent sequence analysis of the
cloned cDNA fragments. For each of the variants, the sequences of twelve
independent
2 o clones were determined. Nucleotide sequence analysis showed multiple
insertions (and
deletions) of A residues downstream of position 44; for CP7-26A, up to 54 As
were
observed (Fig. 2). This demonstrates that each of the variants is genetically
unstable.
For further characterisation of this phenomenon, a full-length cDNA clone
2 s carrying a stretch of 54 A residues (pCP7-54A) downstream of position 44
was
constructed. Transfection of the RNA transcribed from pCP7-54A resulted in
recovery of
infectious virus which was passaged 10 times in MDBK cells and then subjected
to
nucleotide sequence analysis of the 5' NTR. Interestingly, deletions of A
residues were
detected for 11 of 12 investigated clones; for some clones only 5 A residues
were found
30 after position 44 (Fig. 2). As a next step, we constructed the full-length
cDNA clone
pCP7-5A which carries 5 A residues following position 44 using a cloning
strategy
identical to the one described above for construction of e.g. pCP7-9A.
Transfection of
RNA transcribed from pCP7-5A resulted in recovery of the infectious virus CP7-
5A.
3 5 (1) Description of experiments demonstrating that a virus with 5 A
residues
following position 44 is genetically stable.
CA 02342305 2001-04-20
The genetic stability of CP7-5A was investigated after repeated passages in
MDBK cells. After 10 passages, the lengths of 5' NTR fragments were determined
by
RT-PCR analysis using primers OI 200R and 01 CP7-SP6 and subsequent sequence
analysis of the cloned cDNA fragments. Sequence analysis revealed that all 12
investigated clones carried 5 A residues following position 44 (Fig. 2). This
demonstrates that CP7-5A represents a genetically stable variant of BVDV CP7,
while
multiple insertions and deletions of A residues rapidly occurred in the 5' NTR
of the
other variants. Apart from the variiable number of A residues, no other
differences were
observed in any of the analysed 5' NTR clones.
EXAMPLE 2: Materials and methods for generating the 5' NTR mutant viruses
The first set of mutations within the 5' terminal 30 nt of CP7-5A was designed
to
1 5 alter both the nucleotide sequence and predicted RNA secondary-structure
of hairpin la
at various positions. Hairpin la includes a stem which is formed by base-
pairing of nt 1-
10 of the CP7 genome to the complementary sequence of nt 21-30, while the
remaining
10 nt (11-20) form an apical loop. The RNAs of mutants SL-1, SL-2, and SL-3
lack
nucleotide(s) 2, 6-7, and 14-17, respectively. In addition, several mutants
were
2 C) constructed which contain nucleotide substitutions at positions 2-4 (SL-
4), 5-7 (SL-5),
10-13 (SL-6), and 27-29 (SL-7). The RNAs of SL-8, SL-9, delta 2-31, delta 5-
57, and
delta 5-73 lack nucleotides 1-24, 2-29, 2-31, 5-57, and 5-73. The predicted
RNA
secondary structures of the (altered) hairpin la is shown in Fig. 5A.
Construction of all CP7 full-length cDNA clones carrying mutations within the
5' NTR
2 5i was based on the genetically stable cDNA clone pCP7-5A. Generation of the
mutant
cDNAs was performed in two consecutive steps. First, the respective mutation
was
introduced into the 5' terminal sequence of CP7 by PCR with sense primer 01-
SL1, 01-
SL2, 01-SL3, 0I-SL4, 01-SL5, 01-SL6, 0I-SL7, 0I-SL8, 01-SL9, 01-delta 2-31, 01-
delta 5-
57, or 01-delta 5-73 (each encompassing the respective mutated sequence
preceded by
3 0 a Nhel-site and the SP6 RNA polyrnerase promoter) and the antisense primer
01 200R
using pCP7-5A as template. In a second step, Nhel/Xhol fragments of the
resulting
clones were introduced into pCP7'-5A predigested with Nhel and Xhol. The
sequences
of the sense primers are as follows:
3-5) 0I-SL1: 5'-TACGCTAGCATTTAGGTGACACTATAGATACGAGGTTAGGCAAGTTC- 3'
0I-SL2: 5'-TACGCTAGCATTTAGGTGACACTATAGTATAAGGTTAGGCAAGTTC- 3'
01-
SL3: 5'TACGCTAGCATTTAGGTGACACTATAGTATACGAGGTTAAGTTCTCGTATAC
11
CA 02342305 2001-04-20
ATATTGGAC-3'
01-SL4: 5'-
TACGCTAGCATTTAGGTGACA(',TATAGGCGACGAGGTTAGG CAAGTTCTCG-3'
01-SL5: 5'-
TACGCTAGCATTTAGGTGACACTATAGTATGTAAGGTTAGGCAAGTTCTCGTA-3'
01-SL6: 5'-
TACGCTAGCATTTAGGTGACACTATAGTATACGAGAACTG GCAAGTTCTCGTATACATAT-3'
01-SL7: 5 '-TACG CTAGCATTTAGGTGACACTATAGTATACGAG GTTAG GCAAGTTCT
CGTCCCCATATTGGACACTCTAAAAATAATTAG-3'
01-SL8: 5'-TACGCTAGCATTTAGGTGACACTATAGTATACATATTGGACACTCTA-3'
01-SL9: 5 '-TACGCTAGCATTTAG GTGACACTATAGACATATTG GACACTCTAA-3'
Delta 2-31: 5'-
TACG CTAGCATTTAGGTGACACTATAGTATTGGACACTCTAAAAATAATTAG-3'
Delta 5-57: 5'-
TACGCTAGCATTTAGGTGACACTATAGTATCCTAGGGGACAAAAATCCTC-3'
Delta 5-73: 5'-TACGCTAGCATTIf AGGTGACACTATAGTATCCTCCTTAGCGAAGGC-
3'
For all CP7 full-length cDNA clones carrying mutations within the 5' NTR, the
2 0 sequence of the entire 5' NTR was verified by nucleotide sequencing.
Transfection of
full-length genomic RNA transcribed from the cDNA clones carrying the
mutations
resulted in recovery of infectious virus. Transcription of RNA and
transfection of MDBK
cells were carried out as described above.
EXAMPLE 3: Description of the properties of the mutants
For comparative analyses of the properties of the BVDV 5' NTR mutants, the
transcription/transfection experiments using the whole set of mutants were
performed in
3C parallel and repeated several times. These analyses included determination
of the
specific infectivity of the respective genomic RNAs, IFA and determination of
viral yields
after transfection as well as determination of the average plaque size, growth
rate and
yield of the recovered mutant viruses.
After transfection of MDBK cells (as described above) with 2 pg of genomic
RNA,
one tenth of the transfected cells was used for a plaque assay in order to
determine the
specific infectivity of the RNA and the plaque sizes of the recovered viruses.
10-fold
serial dilutions of transfected cells together with 2 x 106 untreated MDBK
cells were
12
CA 02342305 2009-11-04
30339-50
seeded into six-well dishes. After incubation at 37 C for 4 h, the attached
cells were
overlaid with semisolid medium containing 0.6 % low-melting-point agarose
(Gibco-BRL)
and 5 % horse serum. The mutant viruses produced small plaques (0.5 - 1.4 mm)
which
were visualized by immunostaining. After 6 days of incubation at 37 C, the
agarose
overlays were removed, and the cells were washed with PBS and then fixed with
acetone-methanol (1:1) for 1 h at -20 C. After incubation with a mixture of
BVDV E2-
specific monoclonal antibodies for 2 h, monolayers were washed twice with PBS-
0.05 %
Tween 20, and then incubated with peroxidase-conjugated goat anti-mouse
immunoglobulin (1/500 in PBS-0.05 % Tweeri'20; Sigma-Aldrich Chemie GmbH,
lo Steinheim, Germany). After I h, the monolayers were washed twice with PBS
and
plaques were visualized by using the peroxidase substrate 3-amino-9-ethyl-
carbazole
(Sigma-Aldrich Chemie GmbH).
The specific infectivity indicates the number of plaque forming units (PFU)
per pg
RNA. This parameter was determined after transfection of MDBK cells with a
defined
amount of in vitro transcribed genomic RNA by counting the number of
independently
produced viral plaques. For the RNA of CP7-5A, CP7-9A, CP7-20A, and CP7-26A,
the
infectivity was between 2.4 x 105 PFU/pg and 6.0 x 105 PFU/pg, while 8.0 x 10`
PFU/pg
and 8.0 x 102 PFU/pg were obtained for the RNAs transcribed from pCP7-54A and
pCP7-T, respectively (Fig. 3 shows the results of a representative
experiment). The
specific infectivities of alt other 5" NTR mutants with substitutions or
deletions within the
region comprising the predicted hairpins la and lb were significantly reduced
when
compared to the parent construct CP7-5A. The specific infectivities of SL-2,
SL-3, SL-5,
SL-6, SL-7, SL-8, delta 2-31, and delta 5-57 are between 5.2 x 103 PFU/Ng -
6.4 x 10
PFU/pg) and allow the recovery of reasonable amount of infectious progeny
virus (see
below). In contrast, for SL-1, SL-4, SL-9 and delta 5-73, the specific
infectivity was near
or below the level of detection. These differences correlated well with the
amounts of
cells expressing BVDV antigen as determined 24 h p.t. by immunofluorescence
using
Mabs against Ems, E2, and NS3 (see Fig. 3, 5, and 6). The specific
infectivities and the
results of the IFA of all the mutants are shown in Fig. 3, 5, and 6. Mutants
which have at
least 2-fold reduced infectivities (e.g. SL-2, SL-3, SL-5, SL-6, SL-7, SL-8,
delta 2-31,
and delta 5-57) are expected to be attenuated and thus would be useful as a
live
vaccines.
In addition, the virus titers obtained at different time points after
transfection were
determined for all the 5" NTR mutants (Fig. 4, 5, and 6). After the indicated
time
intervals, aliquots (200 pi) of the cell culture supernatant were removed and
used for
titration on MDBK cells. The viral yields were determined as the titer of 50 %
tissue.
*Trade-mark
13
CA 02342305 2001-04-20
culture infectious dosis (TCID50)/ml. When compared to CP7-5A, the virus
titers obtained
1 day after transfection were reduced by a factor of at least 8 for all 5' NTR
mutants.
The respective differences correlated well with the specific infectivities and
the portions
of BVDV antigen-positive cells determined 24 h p.t..
Progeny virus recovered from the in vitro transcribed RNAs of CP7-5A, SL-2, SL-
3, SL-
5, SL-6, SL-7, SL-8, delta 2-31, and delta 5-57 was characterized by plaque
assay on
MDBK cells using dilutions of transfected cells. The transcript-derived parent
virus CP7-
5A formed plaques with an average size of 2.7 mm. Each of the mutants produced
smaller plaques. SL-2, SL-5, and SL-7 produced plaques with an average size
ranging
from 1.2-1.4 mm, while plaques generated by SL-3, SL-6, SL-8, delta 2-31, and
delta 5-
57 had an average size < 0.8 mm. The average plaque sizes of the individual
mutants
are shown in Figure 7. The small plaque phenotype is a significant property of
all 5' NTR
mutants and demonstrates that the respective virus is retarded in growth and
therefore
can be used as a live vaccine virus. For practical purposes, such a mutant
preferably
grows to titers of at least 105 TCID50/ml. After passaging the mutant viruses
in MDBK
cells, we have demonstrated that e.g. delta 2-31 and delta 5-57 reach titres
>106 TCID50.
The plaque phenotype of these passaged virus mutants are identical to the one
observed immediately after transfection (see above).
2 C'
For determination of growth kinetics, supernatants from cells transfected with
the
individual mutant RNAs were titrated and then used to infect 1 x 106 MDBK
cells (in a
six-well dish) at an MOI of 0.05. After adsorption for 1 h at room
temperature, the cells
were washed six times with PBS, and then overlaid with medium containing 10 %
horse
2 5 serum followed by incubation over a 4-days period. After the indicated
time intervals,
aliquots (200 pl) of the cell culture supernatant were removed and used for
titration on
MDBK cells. The viral yields were determined as the titer of 50 % tissue
culture
infectious dosis (TCID50)/ml. The peak titer for CP7-5A and the 5' NTR mutants
was
achieved on day 3 postinfection. Mutants SL-2, SL-3, SL-5, SL-6, and SL-7 were
about
3C 10-fold reduced in their peak titers, while the peak titers reached by
mutants delta 2-31
and delta 5-57 were about 100-fold lower compared to CP7-5A (Fig. 8 A).
Establishment
of growth curves at 33 C and 40.5 C showed that neither CP7-5A nor any of the
mutants exhibited a temperature-sensitive phenotype, at least with regard to
these
temperatures. These results demonstrate that the differences of growth
kinetics
35 correlate with the observed plaque sizes. Moreover, the growth restriction
of the mutant
viruses mirrors the reduction of specific infectivity detected for the
individual RNAs (Fig.
7; see also Fig. 5 and 6). Such growth restricted viruses can be used as live
vaccine
viruses.
14
CA 02342305 2009-11-04
30339-50
For analysis of viral RNA synthesis, 1 x 108 MDBK cells were infected with
transcript-derived virus at a MOI of 0.05 and processed in parallel to cells
used for
determination of the growth kinetics. Total cellular RNA was prepared 2 days
postinfection, and used for Northern blot analysis. Five micrograms of
glyoxylated RNA
was separated in a phosphate-buffered 1.0% agarose gel containing 5.5%
formaldehyde
and transferred to Duralon-UV membranes (Stratagene, Heidelberg, Germany).
Radioactive labelling of the probe, hybridization, and washing conditions were
as
described (J. Virol. 72: 8697-8704). A 2.5-kb Notl-Nsil fragment from the cDNA
done
pABVDV was used as a probe. The viral genomic RNAs were visualized by
autoradiography, and the intensity of bands was determined with a
phosphorimager
(Fig. 8 B). CP7-5A RNA was more abundant than that of any of the mutant
viruses. The
RNA of SL-7 was next followed by lower amounts of RNA for SL-2, SL-3, SL-5,
and SL-
6. As expected based on its replication kinetics, the RNAs of delta 2-31 and
delta 5-57
were least abundant. Northern blot analysis of RNAs prepared 3 days
postinfection led
to very similar results. It can be concluded that the amounts of viral RNAs
detected
correlated with the obtained virus titers.
To investigate the genetic stability, each mutant was repeatedly passaged in
MDBK cells. Using RNAs from the 3rd tissue culture passage, the 5' and 3'
terminal
sequences were amplified by the above described RNA ligation/RT-PCR method and
cloned in a bacterial vector; at least 10 independent clones were
characterized for each
mutant. Sequence analysis indicated the absence of any secondary mutations
within the
analyzed genomic regions of the mutants SL-2, SL-3, SL-5, SL-6, SL-7, SL-8,
delta 2-31
and delta 5-57. In contrast, reversions or secondary mutations were found for
SL-1, SL-
4, SL-9, and delta 5-73. Genetic stability is considered to be an important
criterion for a
genetically engineered live virus vaccine.
After two tissue culture passages of the transfection supernatant of i5-73,
higher
titers of infectious virus (> 105/ml).were obtained. Analysis of the 5'
terminal sequences
derived from 12 independent clones indicated the emergence of mutants with
duplications of 2 nt (Ml) or 3 nt (M2) near the 5' terminus of the genome
(Fig. 6D).
These results suggest that hairpins la and lb are not required for replication
of
pestiviruses, provided the sequence motif 5'-GUAU remains at the 5" terminus
of the
viral RNA.
Two additional mutants, termed R1 and R2, were generated after transfection of
RNAs transcribed from CP7-5A -derived cDNA clones containing the 5' terminal
*Trade-mark
CA 02342305 2009-11-04
30339-50
sequence of mutant virus M1 or M2, which emerged after transfection with the
delta 5-
73 RNA. The mutant viruses R1 and R2 still contain the 5'-GUAU, but lack the
hairpins
la and lb.
The specific infectivities of the RNAs of R1 and R2 were significantly reduced
when
compared to the parent construct CP7-5A.
Further analyses were performed with R2. R2 exhibited a small plaque phenotype
(average size < 1.2 mm). The peak titer of R2 reached in bovine cells was > 10-
fold
lower compared to CP7-5A. Furthermore, the amount of accumulated RNA was
significantly reduced.
EXAMPLE 4: Further studies on the genetic stability of delta2-31, delta5-75
and R2.
To further study the genetic stability, the mutant viruses delta 2-31, delta 5-
57,
and R2 were passaged ten times in MDBK cells. Using RNAs from the 10th tissue
culture passage, the 5' and 3' terminal sequences were amplified by the
described RNA
ligation/RT-PCR method and cloned in a bacterial vector. Sequence analysis of
at least
4 clones for each of the three mutants indicated the absence of any secondary
mutations within the analyzed part of the 5' NTRs. In addition, plaque assays
performed
with the mutant viruses delta 2-31, delta 5-57, and R2 obtained after 10
tissue culture
passages revealed the stability of the small plaque phenotype. The titers of
these
mutants reached in bovine cells were >1000.000/ml.
LEGENDS TO THE FIGURES
FIG. 1. 5' sequences of pestiviruses, in particular BVDV-1 strain CP7. (A)
Alignment of
the 5' terminal sequences of representative strains from the four pestivirus
species. For
BVDV-1 CP7, the consensus sequence was determined from 10 independent clones.
Other sequences were extracted from the GenBank/EMBL database (BVDV-1 Osloss,
BVDV-1 NADL, CSFV Alfort-T, CSFV Brescia, BDV X818, BVDV-2 890). Conserved
nucleotides are indicated with an asterisk. (B) Predicted RNA secondary-
structure of
the 5' NTR of BVDV-1 CP7-9A. Modeling was performed with the computer programs
RNAFOLD, MFOLU and FOLDANALYZE In addition, the proposed structure is based
on comparative sequence analysis. The initiation codon AUG is indicated.
FIG. 2. Multiple insertions and deletions of A residues downstream of position
44 during
propagation of BVDV 5' NTR mutants in bovine cells. After transfection with
engineered.
*Trade-mark
16
CA 02342305 2001-04-20
full-length RNAs, the recovered BVDV mutants CP7-9A, CP7-20A, CP7-26A, CP7-
54A,
and CP7-5A were repeatedly passaged in MDBK cells. After 10 passages, the 5'
NTR
sequences and the numbers of A residues following position 44 were determined
for
each mutant by sequence analysis of 12 independent clones.
FIG. 3. Immunofluorescence (IF) analysis of MDBK cells at 24 h
posttransfection (p.t)
with engineered full-length RNAs of CP7-5A, CP7-9A, CP7-20A, CP7-26A, CP7-54A,
and CP7-T (magnification, x 100). The specific infectivities of the BVDV CP7
mutant
RNAs are indicated.
FIG. 4. Virus titers obtained for BVDV 5' NTR mutants CP7-5A, CP7-9A, CP7-20A,
CP7-26A, CP7-54A, and CP7-T at 24, 48, and 72 h posttransfection. The titers
of
released virus were determined on MDBK cells.
FIG. 5. Hairpin la mutants. (A) Computer-predicted RNA secondary-structures of
BVDV
hairpin la mutations and IF analysis of MDBK cells at 24 h posttransfection
(p.t.) with
full-length RNAs of CP7-5A, SL-1, SL-2, SL-3, SL-4, SL-5, SL-6, SL-7, SL-8,
and SL-9
(magnification, x 100). Modeling was performed with the computer programs
RNAFOLD
and MFOLD. Deleted (A) and substituted nucleotides within hairpin la are
indicated. (B)
2 0 Specific infectivities of the BVDV mutant RNAs in MDBK cells and virus
titers obtained
at 24, 48, and 72 h p.t..
FIG. 6. Deletion of hairpins la and lb. (A) Schematic representation of the 5'
NTR of
BVDV CP7-5A and deletion mutants N2-31, A5-57, and A5-73. (B) IF analysis of
MDBK
cells at 24 h posttransfection (magnification, x 100). (C) Specific
infectivities in MDBK
cells and virus titers obtained at 24, 48, and 72 h p.t.. (D) 5' terminal
sequences of CP7-
5A, A5-73, and mutant viruses M1 and M2 evolved after passaging of
supernatants from
cells transfected with A5-73 RNA. For M1 and M2, the inserted nucleotides are
highlighted.
FIG. 7. Plaques produced by BVDV 5' NTR mutants at day 6 p.t.. (A) Plaque size
of
CP7-5A, SL-2, SL-3, SL-5, SL-6, SL-7, SL-8, A2-31, and A5-57 in MDBK cells.
The
average plaque size of 20 randomly selected plaques is indicated. (B) As
examples, the
plaques generated by CP7-5A, SL-7, and SL-8 are shown.
FIG. 8. (A) Growth curves of BVDV CP7-5A and mutant BVDV strains SL-2, SL-3,
SL-5,
SL-6, SL-7, A2-31, and A5-57 determined on MDBK cells infected at an MOI of
0.05.
The titers of released virus were determined over a 4-day period. (B) Northern
blot
17
CA 02342305 2001-04-20
analysis of total RNA from MDBK cells infected with BVDV CP7-5A and the
indicated
mutant BVDV strains at an MOI of 0.05. The infected cells were processed in
parallel to
those used to determine the growth rates. RNAs were extracted at 48 h after
infection.
The blot was hybridized with a BVDV CP7-specific cDNA fragment. RNA ladder
sizes in
s kilobases (kb) are indicated on the left. The intensity of bands was
determined with a
phosphorimager. The relative amounts of viral genomic RNAs are indicated below
the
blot.
18
CA 02342305 2001-06-14
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: AKZO NOBEL N.V.
(ii) TITLE OF INVENTION: PESTIVIRUS AND VACCINES CONTAINING THE SAME
(iii) NUMBER OF SEQUENCES: 24
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: FETH:ERSTONHAUGH & CO.
(B) STREET: P.O. BOX 2999, STATION D
(C) CITY: OTTAWA
(D) STATE: ONT
(E) COUNTRY: CANADA
(F) ZIP: K1P 5Y6
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Flcppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (text)
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: CA 2,342,305
(B) FILING DATE: 20-APR-2001
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: FETHERSTONHAUGH & CO.
(B) REGISTRATION NUMBER:
(C) REFERENCE/DOCKET NUMBER: 23804-604
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (613)-235-4373
(B) TELEFAX: (613)-232-8440
(2) INFORMATION FOR SEQ ID NO.: 1:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 48
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 1:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT ACGAGGTTAG GCAAGTTC 48
(2) INFORMATION FOR SEQ ID NO.: 2:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 47
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 2:
TACGCTAGCA TTTAGGTGAC ACTATAGATA CGAGGTTAGG CAAGTTC 47
(2) INFORMATION FOR SEQ ID NO.: 3:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 46
19
CA 02342305 2001-06-14
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 3:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT AAGGTTAGGC AAGTTC 46
(2) INFORMATION FOR SEQ ID NO.: 4:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 61
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 4:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT ACGAGGTTAA GTTCTCGTAT ACATATTGGA 60
C 61
(2) INFORMATION FOR SEQ ID NO.: 5:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 51
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 5:
TACGCTAGCA TTTAGGTGAC ACTATAGGCG ACGAGGTTAG GCAAGTTCTC G 51
(2) INFORMATION FOR SEQ ID NO.: 6:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 53
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 6:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT GTAAGGTTAG GCAAGTTCTC GTA 53
(2) INFORMATION FOR SEQ ID NO.: 7:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 60
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 7:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT ACGAGAACTG GCAAGTTCTC GTATACATAT 60
CA 02342305 2001-06-14
(2) INFORMATION FOR SEQ ID NO.: 8:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 82
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 8:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT ACGAGGTTAG GCAAGTTCTC GTCCCCATAT 60
TGGACACTCT AAAAATAATT AG 82
(2) INFORMATION FOR SEQ ID NO.: 9:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 47
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 9:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT ACATATTGGA CACTCTA 47
(2) INFORMATION FOR SEQ ID NO.: 10:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 45
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 10:
TACGCTAGCA TTTAGGTGAC ACTATAGACA TATTGGACAC TCTAA 45
(2) INFORMATION FOR SEQ ID NO.: 11:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 52
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 11:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT TGGACACTCT AAAAATAATT AG 52
(2) INFORMATION FOR SEQ ID NO.: 12:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 50
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 12:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT CCTAGGGGAC AAAAATCCTC 50
21
CA 02342305 2001-06-14
(2) INFORMATION FOR SEQ ID NO.: 13:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 46
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: DNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 13:
TACGCTAGCA TTTAGGTGAC ACTATAGTAT CCTCCTTAGC GAAGGC 46
(2) INFORMATION FOR SEQ ID NO.: 14:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 96
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 14:
GUAUACGAGA UUAGCUAAAG UACUCGUAUA CGGAUUGGAC GUCGACAAAC UUUGAAUUGG 60
CAACACAGGG AACCUUCCCC UCGGCGAAGG CCGAAA 96
(2) INFORMATION FOR SEQ ID NO.: 15:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 88
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 15:
GUAUACGAGG UUAGCUCUUU CUCGUAUACG AUAUUGGAUA CACUAAAUUU CGAUUUGGUC 60
UAGGGCACCC CUCCAGCGAC GGCCGAAA 88
(2) INFORMATION FOR SEQ ID NO.: 16:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 89
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 16:
GUAUACGAGG UUAGUUCAUU CUCGUGUACA UGAUUGGACA AAUCAAAAUC UCAAUUUGGU 60
UCAGGGCCUC CCUCCAGCGA CGGCCGAGC 89
(2) INFORMATION FOR SEQ ID NO.: 17:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 100
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
22
CA 02342305 2001-06-14
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 17:
GUAUACGAGG UUAGGCAAGU UCUCGUAUAC AUAUUGGACA CUCUAAAAAU AAUUAGGCCU 60
AGGGGACAAA AAUCCUCCUU AGCGAAGGCC GAAAAGAGGC 100
(2) INFORMATION FOR SEQ ID NO.: 18:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 98
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 18:
GUAUACGAGG UUAGGCAAGU UCUCGUAUAC AUAUUGGACA CUCUAAAAAA AAAUAAUUAG 60
GCCUAGGGGA CAAAAAUCCU CCUUAGCGAA GGCCGAAA 98
(2) INFORMATION FOR SEQ ID NO.: 19:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 19:
GUAUCCUCCU UAGCGAAGGC CGAAAAGAGG C 31
(2) INFORMATION FOR SEQ ID NO.: 20:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 20:
GUAUAUCCUC CUUAGCGAAG GCCGAAAAGA GGC 33
(2) INFORMATION FOR SEQ ID NO.: 21:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 21:
GUAUCCUCCU CCUUAGCGAA GGCCGAAAAG AGGC 34
(2) INFORMATION FOR SEQ ID NO.: 22:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 96
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
23
CA 02342305 2001-06-14
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 22:
GUAUACGAGA AUUAGAAAAG GCACUCGUAU ACGUAUUGGG CAAUUAAAAA UAAUAAUUAG 60
GCCUAGGGAA CAAAUCCCUC UCAGCGAAGG CCGAAA 96
(2) INFORMATION FOR SEQ ID NO.: 23:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 93
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 23:
GUAUACGAGA AUUUGCCUAA CCUCGUAUAC AUAUUGGGCA UUCUAAAAAU AAAUUAGGCC 60
UAAGGGACAA AUCCUCCUUA GCGAAGGCCG AAA 93
(2) INFORMATION FOR SEQ ID NO.: 24:
(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 87
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: RNA
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Pestivirus sp.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.: 24:
GUAUACGGGA GUAGCUCAUG CCCGUAUACA AAAUUGGAUA UUCCAAAACU CGAUUGGGUU 60
AGGGAGCCCU CCUAGCGACG GCCGAAC 87
24
